MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14 is the first and only therapy approved by the FDA
Photo credit: theepharmatechnicians
Novartis announced on 6 May 2020 that the US Food and Drug Administration (FDA) approved Tabrecta™ (capmatinib, formerly INC280), an oral MET inhibitor for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14) as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Sign up for the editor pick and get articles like this delivered right to your inbox.